Diversity in clinical trial recruitment means enrolling a study population whose age, sex, race, ethnicity, and health status reflect the patients who will eventually take the approved treatment, not just the people who live closest to a trial site.
The requirement now carries statutory weight: the Food and Drug Omnibus Reform Act requires sponsors of covered pivotal trials to submit a Diversity Action Plan setting enrollment goals across those categories. Academic journals and pharmaceutical publishers have spent years making the case for why that matters. Almost none of them explain how a CRO or sponsor marketing team finds and enrolls the patients a plan like that requires. This guide covers what the term means, the science and regulation behind it, the barriers that narrow trial populations, and the tactics that close the gap.
What Counts As Diversity In Clinical Trial Recruitment?
That is a different question from how a trial fills its overall enrollment funnel or how an individual site recruits from its own local population; this piece focuses on reaching the demographic groups a trial's usual channels tend to miss. FDA's current framework asks sponsors to plan around age, sex, race, and ethnicity, but geography and comorbidity burden shape real-world representation just as much.
Most of that outreach runs through the same channel CROs already rely on to keep a trial's overall funnel full: geo-targeted Meta and Google campaigns built site by site, covered in how geo-targeted paid media fills trials. What changes for underrepresented populations is where those campaigns point and what the creative says, which the tactics section below covers.
Why Diverse Trial Enrollment Matters Scientifically
Drug response varies with genetics, metabolism, and comorbidity patterns that cluster differently across demographic groups. A trial population that skews narrow can therefore miss safety or efficacy signals relevant to the patients who take the treatment once it reaches the market, a point a New England Journal of Medicine analysis of diverse trial participation makes. Cardiology research shows the pattern in practice: women have historically made up a minority of participants in major cardiovascular drug and device trials, even though heart disease presents and progresses differently by sex. Regulators built the current Diversity Action Plan requirement to catch gaps like that before a treatment reaches patients who were never represented in the evidence behind it.
The FDA Diversity Action Plan: Where The Requirement Stands Today
The Food and Drug Omnibus Reform Act (FDORA) requires sponsors of covered pivotal trials to submit a Diversity Action Plan with enrollment goals by age, sex, race, and ethnicity. As of this writing, FDA's guidance on how those plans will be evaluated remains unfinalized, and the regulatory picture has shifted more than once since 2025. FDA published draft guidance, then removed it, then reinstated it after legal challenge, and the agency has not finalized an evaluation timeline sponsors can treat as settled. That sequence matters more than any single date. Sponsors and CROs planning a Diversity Action Plan should confirm the current requirement directly against FDA's own published reporting on Diversity Action Plans rather than a secondhand summary, including this one, since the status can shift again before this guide's next update. The statutory basis (the requirement to submit a plan at all) is settled; the evaluation details are not.
Barriers That Keep Trials From Reflecting Real Patient Populations
The barriers that keep trial populations narrow are historical mistrust of medical research in some communities, geographic distance from trial sites, language and health-literacy gaps, and the practical burden of participating, including time off work and travel costs, per a PubMed Central review of clinical trial diversity barriers.
Mistrust is rooted in documented historical research abuses and in ongoing experiences of bias in medical care. No ad campaign closes that gap on its own; it takes a trusted local partner, covered in the tactics section below.
Trial sites concentrate at academic medical centers, which cluster in a small number of metro areas, so patients outside those areas face travel time and cost before they reach a screening appointment.
Language and health-literacy gaps shut out patients before they see a recruitment ad, when materials exist only in English or use clinical language a general reader would not recognize.
The practical burden of participating (lost wages, transportation, childcare, and time away from work) falls hardest on lower-income patients, who are also disproportionately represented among the demographic groups Diversity Action Plans exist to reach.
Practical Recruitment Tactics For Underrepresented Populations
Reaching underrepresented patients for a clinical trial takes the same discipline as any geo-targeted media campaign: the right communities, the right creative, and partners the community already trusts.
Community partnerships. Health centers, faith-based organizations, and local physician networks make better referral partners than cold outreach because trust transfers from an institution the community already knows.
Language and cultural fit in creative. Native-language ad copy, not machine-translated or dubbed video, removes a barrier before a patient clicks. So does messaging built around a community's specific concerns instead of a generic trial announcement. Spanish-language creative alone opens up many of the patients most U.S. recruitment campaigns miss by defaulting to English-only ads.
Geo-targeted paid media in underrepresented communities. Ad platforms can target by zip code and neighborhood where a condition disproportionately affects an underrepresented population. That targeting runs on geography and demographic or interest-based signals, not health data. Building an audience from a condition list or inferred health status is not allowed on any major platform, and every recruitment ad goes through IRB review before it runs. That review shapes IRB-reviewed paid media built for healthcare brands across other regulated verticals.
This is the same targeting and creative model Brighter Click runs for CRO clients, not a diversity-specific claim. On the Adams Clinical account, hyperlocal, site-by-site geo-targeting helped one CRO cut CPL 45.9 percent as monthly media buying scaled from $360,000 to $600,000, with click-to-conversion up 91.5% and cost per lead landing between $20 and $39 depending on the trial and condition. The mechanism, tight geography plus condition-relevant creative, applies to underrepresented-community targeting.
Decentralized elements, like a remote visit option or mobile screening unit, can further reduce the geographic burden for patients who cannot reach a fixed site easily, alongside the community and geo-targeting tactics above.
The table below maps each barrier from the previous section to the tactic built to answer it.
How To Know If Your Recruitment Is Actually More Representative
The only reliable way to know if recruitment tactics are working is to track the screening funnel by demographic subgroup, not just watch total enrollment climb toward its target.
Where a trial has a stated Diversity Action Plan, subgroup enrollment numbers should be compared against those stated goals on a recurring basis, not reviewed once near the end of the enrollment window.
Working With A Recruitment Partner
Most CROs and sponsors bring in a paid-media or clinical recruitment partner rather than build a geo-targeted, multilingual program in-house. Some want a full-service company that also handles call-center screening and site coordination; others compare vetted clinical recruitment partners and pick a media-buying specialist while keeping screening in-house. Brighter Click publishes what a CRO recruitment engagement covers, from geo-targeted campaign structure to IRB-batched creative production, so scope is clear before any contract conversation.
Build A Recruitment Plan That Reaches The Patients Your Trial Is Missing
Diversity Action Plans put a name and enrollment goals on a longstanding problem: the patients closest to a trial site rarely look like the patients who will eventually take the approved treatment. Community partnerships, in-language creative, and geo-targeted paid media close that gap without touching protected health data.
Brighter Click runs geo-targeted paid media patient recruitment for CRO and sponsor clients, never UGC production, on the clinical side. Book a free consultation with the founder to discuss your trial's sites and enrollment goals.
Frequently Asked Questions
What Are The Barriers To Diversity In Clinical Trials?
The main barriers are historical mistrust of medical research in some communities, geographic distance from trial sites, language and health-literacy gaps, and the practical burden of participation, including time off work and travel costs. Narrow eligibility criteria and site networks concentrated at academic medical centers add structural barriers on the sponsor side. Most of these are operational problems, which means recruitment teams can address them directly.
Why Is Diversity Important In Clinical Trials?
Drug response can vary with genetics, metabolism, and comorbidity patterns that differ across demographic groups, so a trial population that skews narrow can miss safety or efficacy signals that matter to the patients who will actually take the treatment once approved. United States law now requires sponsors of covered pivotal trials to plan for representative enrollment by age, sex, race, and ethnicity.
What Strategies Improve Racial And Ethnic Diversity In Clinical Trial Recruitment?
The strategies that work answer a specific barrier. Community partnerships with health centers, faith organizations, and local physicians address trust. In-language, culturally specific creative addresses language and literacy gaps. Geo-targeted outreach in the neighborhoods where underrepresented patients live addresses distance and awareness. Reimbursing travel and time addresses participation burden. Broadening eligibility criteria and adding community-based sites address structural exclusion.
How Do Sponsors Build Trust With Underserved Communities For Research?
Trust is built through partners the community already knows, not through advertising alone. Sponsors that work with community health centers, faith-based organizations, and trusted local physicians borrow credibility that a cold ad cannot earn on its own. Community advisory input during trial design, transparent consent materials, and returning results to participants all signal that the relationship runs both ways.
Does Covering Travel And Other Costs Improve Diversity In Trial Recruitment?
Yes. The cost of participating, including travel, parking, lodging, childcare, and lost wages, is a documented barrier that falls hardest on lower-income patients. Reimbursing those costs removes a practical reason to decline. Regulators and IRBs generally distinguish reasonable reimbursement for expenses and time from undue inducement, per FDA's information sheet on payment and reimbursement to research subjects, so sponsors should build a reimbursement plan into the protocol and have the IRB review it.
What Is An FDA Diversity Action Plan?
A Diversity Action Plan is a document that United States law, the Food and Drug Omnibus Reform Act, requires sponsors of covered pivotal trials to submit, setting enrollment goals by age, sex, race, and ethnicity and describing how the trial will meet them. FDA's guidance on how these plans will be evaluated has shifted several times since 2025 and remains unfinalized, so sponsors should verify the current requirement directly with FDA before relying on any summary, including this one.
Can Geo-Targeted Ads Help Recruit A More Diverse Trial Population?
Yes, when the targeting is built on geography and demographics rather than health data. Ad platforms can reach specific zip codes and neighborhoods where a condition disproportionately affects underrepresented groups, putting trial awareness in front of patients that site-adjacent outreach misses. Two guardrails apply: audiences are never built from condition lists or inferred health status, and every ad still goes through IRB review before it runs.
Is Community-Based Or Digital Recruitment Better For Reaching Diverse Populations?
Neither replaces the other; they answer different barriers. Community-based recruitment through health centers, faith organizations, and local events builds trust that historically underrepresented groups often need before considering a trial. Digital recruitment, including geo-targeted paid media, adds reach and speed that community channels alone cannot match. The strongest programs run both and route digital respondents toward locally trusted sites and staff.
